| Name | Title | Contact Details |
|---|---|---|
Kevin Chen |
Co Founder and Chief Executive Officer | Profile |
Quintiles is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.
Somaxon Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics.